IHC-KI 67 MARKER

The IHC – Ki-67 Marker test is an advanced immunohistochemistry (IHC) diagnostic test used to measure cell proliferation activity in tissue samples. Ki-67 is a protein found in actively dividing cells and is widely used as a marker to determine how quickly tumor cells are growing and multiplying.

This test plays a critical role in modern pathology because the Ki-67 proliferation index provides important information about tumor aggressiveness. A higher Ki-67 index generally indicates rapid tumor growth and may suggest a more aggressive cancer, while a lower Ki-67 index often indicates slower-growing tumors.

The Ki-67 marker is commonly used in diagnosing and evaluating many cancers, including breast cancer, lymphoma, brain tumors, neuroendocrine tumors, prostate cancer, and other solid tumors. It helps doctors assess prognosis and guide personalized treatment decisions.

The Ki-67 IHC test is often performed along with other markers such as ER, PR, HER2, p53, CD markers, and tumor-specific biomarkers for comprehensive cancer profiling.

Benefits of the Test

The Ki-67 Marker test offers several important clinical benefits:

• Measures tumor cell growth rate
• Assesses cancer aggressiveness
• Helps predict prognosis
• Supports accurate tumor grading
• Assists in treatment planning
• Helps monitor response to therapy

This test is essential for personalized cancer management.

Why Doctors Recommend This Test

Doctors recommend the Ki-67 test when evaluating cancer growth behavior and planning treatment.

It is commonly advised for:

• Breast cancer evaluation
• Lymphoma diagnosis and grading
• Brain tumor classification
• Neuroendocrine tumor assessment
• Monitoring tumor progression
• Personalized oncology treatment planning

The results help oncologists determine the most appropriate treatment strategy.

Preparation Before Test

No special preparation is required from the patient. The test is performed on previously collected tissue biopsy or surgical specimens.

Normal Reporting Time

The usual turnaround time for the Ki-67 IHC test is 2 to 5 working days, depending on tissue complexity and laboratory workflow.

Who Should Take This Test

This test is recommended for:

• Patients diagnosed with cancer
• Individuals requiring tumor proliferation assessment
• Patients needing tumor grading confirmation
• Cases requiring prognosis evaluation
• Oncology patients needing personalized treatment planning

The IHC Ki-67 Marker test is an essential diagnostic tool in modern oncology. It helps measure tumor growth activity, supports precise tumor classification, and guides effective treatment decisions for improved patient outcomes.